Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 26;14(15):3627.
doi: 10.3390/cancers14153627.

Proton Beam Therapy versus Photon Radiotherapy for Stage I Non-Small Cell Lung Cancer

Yang-Gun Suh  1 , Jae Myoung Noh  2 , Doo Yeul Lee  1 , Tae Hyun Kim  1 , Unurjargal Bayasgalan  1   3 , Hongryull Pyo  2 , Sung Ho Moon  1
Affiliations

Proton Beam Therapy versus Photon Radiotherapy for Stage I Non-Small Cell Lung Cancer

Yang-Gun Suh et al. Cancers (Basel). .

Abstract

Proton beam therapy (PBT) and photon radiotherapy for stage I non-small cell lung cancer (NSCLC) were compared in terms of clinical outcomes and dosimetry. Data were obtained from patients who underwent PBT or photon radiotherapy at two institutions-the only two facilities where PBT is available in the Republic of Korea. Multivariate Cox proportional hazards models and propensity score-matched analyses were used to compare local progression-free survival (PFS) and overall survival (OS). Survival and radiation exposure to the lungs were compared in the matched population. Of 289 patients included in the analyses, 112 and 177 underwent PBT and photon radiotherapy, respectively. With a median follow-up duration of 27 months, the 2-year local PFS and OS rates were 94.0% and 83.0%, respectively. In the multivariate analysis, a biologically effective dose (BED10, using α/β = 10 Gy) of ≥125 cobalt gray equivalents was significantly associated with improved local PFS and OS. In the matched analyses, the local PFS and OS did not differ between groups. However, PBT showed significantly lower lung and heart radiation exposure in the mean dose, V5, and V10 than photon radiotherapy. PBT significantly reduced radiation exposure to the heart and lungs without worsening disease control in stage I NSCLC patients.

Keywords: dosimetric comparison; hypofractionated radiotherapy; non-small cell lung cancer; proton beam therapy; stereotactic ablative radiotherapy; stereotactic body radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Kaplan–Meier plot of local progression-free survival, progression-free survival, and overall survival rates for all patients over 48 months (A). Kaplan–Meier plot of local progression-free survival (B), progression-free survival (C), and overall survival rates (D) for matched patients according to radiotherapy techniques over 48 months. PFS, progression-free survival; OS, overall survival.
Figure 2
Figure 2
Forest plots of Cox proportional hazards regression model. Local progression-free survival (A). Overall survival (B). * <0.05; ** <0.01.
Figure 3
Figure 3
Radiation dose–response analysis. The blue line indicates the predicted local control rate determined by a generalized linear model according to the biologically equivalent dose using α/β = 10 Gy (BED10). The red circles indicate estimated local control rates for groups by radiation dose categories. The radiation dose categories were BED10 of 75–90 (n = 45), 90–110 (n = 23), 110–130 (n = 61), and 130–150 CGE (n = 160). The estimated local control rates for these categories were 86.7%, 82.6%, 93.4%, and 97.5%, respectively.
Figure 4
Figure 4
Box plot of mean radiation doses to the lung (A) and heart (B). Box plot of distributions of dose–volume indices for the lung (C) and heart (D). Whiskers indicate 1.5 times the interquartile range above and below the mean; dots represent individual observation. CGE, cobalt gray equivalent; ns, non-significant; ** <0.01; *** <0.001; **** <0.0001.
See this image and copyright information in PMC

References

    1. Baumann P., Nyman J., Hoyer M., Wennberg B., Gagliardi G., Lax I., Drugge N., Ekberg L., Friesland S., Johansson K.-A., et al. Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy. J. Clin. Oncol. 2009;27:3290–3296. doi: 10.1200/JCO.2008.21.5681. - DOI - PubMed
    1. Timmerman R., Paulus R., Galvin J., Michalski J., Straube W., Bradley J., Fakiris A., Bezjak A., Videtic G., Johnstone D., et al. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer. JAMA. 2010;303:1070–1076. doi: 10.1001/jama.2010.261. - DOI - PMC - PubMed
    1. Videtic G.M., Hu C., Singh A.K., Chang J.Y., Parker W., Olivier K.R., Schild S.E., Komaki R., Urbanic J.J., Timmerman R.D., et al. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927) Int. J. Radiat. Oncol. Biol. Phys. 2015;93:757–764. doi: 10.1016/j.ijrobp.2015.07.2260. - DOI - PMC - PubMed
    1. Timmerman R., McGarry R., Yiannoutsos C., Papiez L., Tudor K., DeLuca J., Ewing M., Abdulrahman R., DesRosiers C., Williams M., et al. Excessive Toxicity When Treating Central Tumors in a phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer. J. Clin. Oncol. 2006;24:4833–4839. doi: 10.1200/JCO.2006.07.5937. - DOI - PubMed
    1. Lindberg K., Grozman V., Karlsson K., Lindberg S., Lax I., Wersäll P., Persson G.F., Josipovic M., Khalil A.A., Moeller D.S., et al. The HILUS-Trial-A Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Ste-reotactic Body Radiotherapy. J. Thorac. Oncol. 2021;16:1200–1210. doi: 10.1016/j.jtho.2021.03.019. - DOI - PubMed

LinkOut - more resources